User profiles for J Stowe

Julia Stowe

- Verified email at phe.gov.uk - Cited by 14534

John D. Stowe

- Verified email at ohio.edu - Cited by 3335

James D Stowe

- Verified email at marc.org - Cited by 657

Examining Rowe and Kahn's concept of successful aging: Importance of taking a life course perspective

JD Stowe, TM Cooney - The Gerontologist, 2015 - academic.oup.com
Purpose of the Study: This article critiques Rowe and Kahn’s conceptualization of successful
aging using tenets of the life course perspective. Design and Methods: A review and …

[HTML][HTML] Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant

…, R Simmons, S Thelwall, J Stowe… - The New England …, 2021 - ncbi.nlm.nih.gov
Background The B. 1.617. 2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …

[HTML][HTML] Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant

…, R Simmons, S Thelwall, J Stowe… - … England Journal of …, 2021 - Mass Medical Soc
Background The B.1.617.2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England …

JL Bernal, N Andrews, C Gower, C Robertson, J Stowe… - bmj, 2021 - bmj.com
Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and
Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the …

[HTML][HTML] Duration of protection against mild and severe disease by Covid-19 vaccines

N Andrews, E Tessier, J Stowe, C Gower… - … England Journal of …, 2022 - Mass Medical Soc
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …

[HTML][HTML] Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant

N Andrews, J Stowe, F Kirsebom, S Toffa… - … England Journal of …, 2022 - Mass Medical Soc
Background A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the
omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly …

[HTML][HTML] Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England

N Andrews, J Stowe, F Kirsebom, S Toffa… - Nature medicine, 2022 - nature.com
Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in
England starting on 14 September 2021. We used a test-negative case–control design to …

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre …

…, E Wellington, J Stowe, N Gillson, A Atti, J Islam… - The Lancet, 2021 - thelancet.com
Background BNT162b2 mRNA and ChAdOx1 nCOV-19 adenoviral vector vaccines have
been rapidly rolled out in the UK from December, 2020. We aimed to determine the factors …

Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1. 529) variant of concern

N Andrews, J Stowe, F Kirsebom, S Toffa, T Rickeard… - MedRxiv, 2021 - medrxiv.org
Background A rapid increase in cases due to the SARS-CoV-2 Omicron (B.1.1.529) variant
in highly vaccinated populations has raised concerns about the effectiveness of current …

Product risk, asymmetric information, and trade credit

YW Lee, JD Stowe - Journal of Financial and Quantitative analysis, 1993 - cambridge.org
The purpose of this paper is to explain cross-sectional variations in trade credit terms across
firms and industries. This study shows that there is a separating equilibrium in which the …